日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

您現在的位置: > Language Tips > Audio & Video > Special Speed News  
 





  Once-daily pill could simplify HIV treatment
[ 2006-02-06 15:57 ]


I’m Steve Ember with the VOA Special English Health Report.


Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

Experts say more than forty million people around the world are living with H.I.V.

This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

Vocabulary

 

 

 
 
 




主站蜘蛛池模板: 久久久久久久久久久91 | 欧美国产一区二区 | 村上凉子av| 日韩中文字幕在线观看 | 操你啦在线| 成人黄色在线免费观看 | 三级视频在线播放 | 成人看片在线 | 一级片一级片一级片 | aaa日韩| 一区二区三区蜜桃 | 福利视频在线导航 | 日本人の夫妇交换 | 欧美激情综合色综合啪啪五月 | 国产三级精品三级观看 | 午夜精品久久久久久 | 国产高清久久久 | 操碰| 欧美精品免费一区二区三区 | 最近2019中文字幕大全第二页 | 奶波霸巨乳一二三区乳 | 踩踏天堂 | 久操视频网 | 久久99免费 | 国产精品久久久久久亚洲毛片 | 欧美日韩精品在线 | 欧美日韩一区视频 | 黄色片毛片 | 精品白浆| 日本不卡久久 | 日韩美女中文字幕 | 日韩1级片 | 久久成年人视频 | 天堂社区av | 久久精品在线观看 | 久久成人综合网 | 色婷婷影视 | 香蕉伊人网 | 一级黄色大片免费观看 | 精品久久视频 | 欧美一区二区三区观看 |